23andMe gets FDA clearance for prostate cancer risk test

The Verge / January 10, 2022

Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk….


Read more: https://www.theverge.com/2022/1/10/22876615/23andme-fda-prostate-cancer-risk-test